The present disclosure relates to use of an anti-PD-1 antibody and/or an antigen-binding fragment thereof in the treatment of a neuroendocrine neoplasm. The present disclosure also relates to an agent or a kit for detecting an ARID1A gene mutation or amplification, or a chromosomal gene rearrangement, and use of the detection agent or kit in predicting the therapeutic effect of an anti-PD-1 antibody or an antigen-binding fragment thereof in the treatment of a patient with a neuroendocrine neoplasm.

Provided herein are methods for treating, reducing or preventing influenza A virus infection in a patient, as well as compositions and articles of manufacture for treating, reducing or preventing influenza A virus infection in a patient.

The invention relates to the novel use of an immunogenic formulation containing Bacillus Calmette-Guerin (BCG) in a concentration between 10.sup.4-10.sup.9 bacteria, which recombinantly expresses at least one protein or immunogenic fragment of the human Respiratory Syncytial Virus (hRSV, human orthopneumovirus), stabilized in a pharmaceutically acceptable saline buffer solution to prevent, treat, or attenuate bRSV infections in cattle.

Embodiments of the disclosure include methods and compositions for inhibiting the immune suppressive tumor microenvironment using cell therapy wherein the cells express a chimeric protein having an extracellular domain that binds TRAIL-R2 and an intracellular domain that in specific embodiments comprises one or more costimulatory domains that enhance activity of the cells upon activation. In specific embodiments, the chimeric protein comprises an scFv that targets TRAIL-R2 and an intracellular region that comprises a costimulatory domain from 4-1BB. In particular embodiments, the cells also express a therapeutic protein, such as a chimeric antigen receptor.

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CD3 protein. The antibodies of the present technology are useful in methods for detecting and treating cancer or a CD3 -associated pathology in a subject in need thereof.

Methods and compositions for treating, inhibiting, and/or preventing the progression of osteoarthritis comprise compositions that blocks or inhibits the expression, induction, activity, or signaling of LRRC15 protein or the expression, transcription or activity of the LRRC15 gene and administering such compositions to a human subject having osteoarthritis and in need thereof.

This document provides methods and materials for using umbilical cord blood to treat non-malignant disorders. For example, methods and materials for administering umbilical cord blood to a mammal (e.g., a human) via multiple (e.g., two or more) infusions to treat non-malignant diseases such as inherited disorders of metabolism, immunity, and/or hematopoiesis are provided.

The present application relates to methods using Transforming Growth Factor-β (TGF-β) ligand traps. The TGF-β ligand traps described herein may be suitable for combination therapy with an immunotherapy, for treating a disease or disorder such as a cancer. The TGF-β ligand traps described herein may also be suitable for monotherapy for treating a disease or disorder such as a cancer. In particular, provided herein are methods and compositions for treating a disease or disorder such as a cancer by administering a TGF-β ligand trap in combination with an immune checkpoint inhibitor.

A method of treating systemic sclerosis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or bind to the cartilage or kidney of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of an active agent to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures, or cells targeted by the peptide.